Optimizing AML treatment based on early response
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if adjusting chemotherapy based on early signs of leukemia can improve outcomes for people newly diagnosed with acute myeloid leukemia (AML). It might be a good fit if you are starting treatment and have a certain level of leukemia cells in your blood after a few days of therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with acute myeloid leukemia (AML).
- You are 18 years or older.
- Your overall health allows for daily activities (ECOG score 0-2).
- Your kidneys and liver are working well enough as determined by blood and urine tests.
- You have at least 1% leukemia cells in your blood 6 days after starting chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the drug venetoclax works in people newly diagnosed with acute myeloid leukemia (AML). It helps doctors understand the right dose for better results.
This trial compares two different strengths of a chemotherapy regimen that includes venetoclax (a targeted pill) for people with newly diagnosed acute myeloid leukemia (AML). The goal is to find which dose works as well or better with fewer side effects, and it may offer a more personalized treatment option for those who can tolerate intensive therapy.
This study tests whether using a genetic profile of your leukemia plus a very sensitive test for leftover cancer cells can guide a more personalized treatment plan. The goal is to give you the most effective therapy while avoiding unnecessary side effects.
This trial tests whether one initial chemotherapy approach works better than another in people newly diagnosed with high-risk acute myeloid leukemia (AML). You may benefit if your disease is high-risk, and the study will also compare how well the treatments control the leukemia and how safely they work.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.